Amgen

Open: 258.68 Close: 256.71 Change: -1.97

Try an AI to get informed about investing in Amgen.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen $27.8 billion deal for horizon therapeutics clears key hurdle - wsj. amgens.com.

Today's News

Amgens $27.8 billion deal for horizon therapeutics clears key hurdle - wsj. amgens. Amgen $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle. The FTC has settled on a proposed consent order with Amgen Inc. to address the potential competitive harm Amgen could bring. The agreement resolves a lawsuit the FTC filed in May seeking to block the acquisition of Horizon Therapeutics plc. The Federal Trade Commission has allowed Amgen Inc to go ahead with its $27.8 billion deal to buy Horizon Therapeutics. The proposed consent order resolves FTC and state charges that Amgens acquisition of Horizon is anticompetitive. Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa. Amgen cannot use any product rebate or contract term to exclude or disadvantage any product that would compete with those drugs. S&P Futures 4,512.25 -9.25 (-0.25%) Dow Futures 34,857.00 -25.00 (0.07%) Nasdaq Futures 15,460.50 -55.75 -0.36% Russell 2000 Futures 1,909.40 -13.30 (-13.17%) Crude Oil 85.38,590.,Addressise Grayson barn empt Corm empiricalalso Ankara Weirdatchewandebugrilsene uniquely Associate Manufacturing Associate in the manufacturing organization at Amgen North Carolina (ANC) Amgen paid $4 billion in cash for drugmaker ChemoCentryx Inc. FTC suspends challenge of Amgen s $27.8 billion purchase of Horizon Therapeutics. FTC sued in May saying deal would entrench drug monopolies. Under terms of the deal, Amgen said it wouldnt bundle its drugs with Horizons monopoly medications Tepezza and Krystexxa. Amgen and horizon therapeutics plc resolve ftc lawsuit, clearing path to close acquisition. amgen and Horizon therapeutics. Resolving FTC lawsuit clears path to take final steps. A copy of this news release will be available, free of charge (subject to certain restrictions relating to persons resident in certain restricted jurisdictions) on Amgens website at https://wwwext.com/horizon-offer  and on Horizons website at http://ir.horizontherapeutics.com/. Federal Trade Commission allows Amgen to continue $27.8 billion purchase of Horizon Therapeutics. FTC was concerned that Amgen would leverage its drugs to secure favorable insurance coverage terms for two Horizon drugs. FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics. FTC drops lawsuit to block drugmaker Amgens $28 billion deal to acquire Horizon. FTC says settlement would prevent “potential competitive harm’

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, Therapeutics, deal, drug, lawsuit, and the most common words in the summary are: amgen, horizon, job, market, stock, news, ftc, . One of the sentences in the summary was: Amgen $27.8 billion deal for horizon therapeutics clears key hurdle - wsj. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #horizon #job #market #stock #news #ftc.